Advicenne Presented Additional Efficacy Data on ADV7103 in the Treatment of dRTA at International Pediatric Nephrology Association Congress
October 28, 2019
Advicenne (Euronext: ADVIC – FR0013296746), a specialty pharmaceutical company focused on the development and commercialization of therapeutic products for rare kidney disease, is pleased to announce oral and poster presentations on its lead drug candidate, ADV7103, given at the 18th congress of the International Pediatric Nephrology Association (IPNA). Advicenne also organized a symposium at the October congress.